Floatz logo

FLUOROURACILUM

Acquired Resistance to KRAS G12C Inhibitor

Institut de Recherches Internationales ServierSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Acquired Resistance to KRAS G12C Inhibitor cohort.

Asset / SponsorPhaseRating
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC
PANITUMUMAB
Institut de Recherches Internationales Servier
Phase 1/2CCC
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →